Search Results 701-710 of 18372 for prostate cancer
The primary hypotheses are that the TULSA-Procedure is safe and effective treatment of intermediate grade prostate cancer over 2 years. The primary endpoint ...
This is an open label, phase I/II, multi-center study in adult participants with metastatic hormone sensitive prostate cancer (mHSPC) and with metastatic ...
Positron Emission Tomography Using 64Cu-SAR-bisPSMA In Participants With High-risk Prostate Cancer Prior To Radical Prostatectomy · More about research at Mayo ...
... prostate cancer. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...
Giving carboplatin with the standard of care chemotherapy drug cabazitaxel may be better at treating metastatic castrate-resistant prostate cancer.
Pancreatic cancer. Prostate cancer. Rectal cancer. Sarcoma. Skull base tumors. Spinal cord tumors. Spinal tumor and spinal mass. Vertebral ...
The purpose of this study is to evaluate and validate our novel 3D DWI for detection and characterization of prostate cancer. Participation eligibility.
Hormone therapy for prostate cancer. Research. With state-of-the-art lab space and leading physician-researchers in the Department ...
cancer survivor, but it's possible to predict some of what the survivor might experience based on the type of cancer. For example, both prostate cancer and its ...
With some special help from his doctors, Tommy. Archer outraced prostate cancer in order to be there. Here's Dennis Douda for the Mayo Clinic News. Network ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.